compounded semaglutide lawsuit Novo Nordisk CEO Maziar Mike Doustdar says it’s suing Hims & Hers for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Read more Novo Nordisk Sues Hims Over

If you enjoy variety, keep an eye on special themes tied to new slot launches

Whether you are considering starting GLP-1 therapy or you are already months into treatment and wondering what comes next, this is the reference guide you will keep coming back to

Lean C57BL/6J mice were injected with semaglutide and then LPS

BMI 30 or higher strong chance of coverage BMI 27+ with a weight-related condition may qualify with a supporting diagnosis Employer plan rules coverage limits and approved medications vary Prior authorization required WeightWatchers helps you navigate the paperwork Insurance can bring your monthly medication cost down to as little as $0$100/month

Diabetes Obes Metab 25(1):5667 Rosenstock J, Wysham C, Frias JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Walk at Home on You Tube) Incorporate strength training into your routine (ie